Quest Group Intl - Series A preferred stock, $.001 par value,...

Quest Group Intl - Recent Material Event

Item 1.	Condensed Financial Statements	2
	Item 2.	Management’s Discussion and Analysis or Plan of Operation.	12
	Item 3.	Controls and Procedures	15

PART II	OTHER INFORMATION

	Item 1.	Legal Proceedings	17
	Item 2.	Unregistered Sales of Equity Securities and Use of Proceeds	17
	Item 3.	Defaults Upon Senior Securities	17
	Item 4.	Submission of Matters to a Vote of Security Holders	17
	Item 5.	Other Information	17
	Item 6.	Exhibits.	17

SIGNATURES			18
EXHIBIT INDEX			19

PART I

FINANCIAL INFORMATION

Item 1.

Condensed Financial Statements

NuRx Pharmaceuticals, Inc.

(a corporation in the development stage)

Condensed Balance Sheets

As of March 31, 2008 and September 30, 2007

	March 31, 2008 (unaudited)			September 30, 2007

ASSETS

Cash and cash equivalents	$	13,656,522		$	14,941,723
Prepaid expenses		19,627			55,832

Total current assets		13,676,149			14,997,555

Property & equipment, net of accumulated depreciation and amortization of $5,342 and $1,382		34,183			27,825

Deposits		42,093			27,093

Total assets	$	13,752,425		$	15,052,473

LIABILITIES AND STOCKHOLDERS' EQUITY

Accounts payable and accrued expenses	$	371,507		$	103,441
Due to related parties		-			36,090
Total current liabilities		371,507			139,531

Commitments and contingencies		-			-

Stockholders' Equity
Series A preferred stock, $.001 par value, 1,000,000 shares designated, no shares issued and outstanding		-			-
Series B preferred stock, $.001 par value, 500,000 shares designated, no shares issued and outstanding		-			-
Common stock, $.001 par value, 150,000,000 shares authorized, respectively, 121,335,927 and 114,259,000 shares issued, respectively, and 113,576,927 and 106,550,000 shares outstanding, respectively		121,336			114,309
Additional paid-in capital		22,098,887			18,467,156
Treasury stock		(750,000	)		(750,000	)
Accumulated deficit during development stage		(8,125,505	)		(2,954,723	)
Retained earnings		36,200			36,200

Total stockholders' equity		13,380,918			14,912,942

Total liabilities and stockholders' equity	$	13,752,425		$	15,052,473

See Notes to Condensed Financial Statements

NuRx Pharmaceuticals, Inc.

(a corporation in the development stage)

Condensed Statements of Operations (unaudited)

For the three and six months ended March 31, 2008 and March 31, 2007, and development stage from inception (May 1, 2007) through March 31, 2008

	Three months ended March 31					Six months ended March 31					Inception (May 1, 2007) through
											March 31, 2008

Operating Expenses:
General & administrative (includes stock based compensation of $62,808, $0, $116,808, $0, and $182,637, related party consulting fees of $94,500, $0, $187,500 , $0, and $352,200 respectively)	$	642,975		$	-	$	1,264,730		$	-	$	2,083,326

Research & clinical development (includes stock based compensation of $4,475, $0, $8,950 , $0, and $8,950, related party consulting fees of $50,000, $0, $85,577, $0 and $ 91,667 respectively, and fair value of shares of $3,513,000 issued in connection with milestone payment)		417,560			-		4,185,795			-		6,572,944
Total operating expenses		1,060,535			-		5,450,525			-		8,656,270

Other income and (expense)
Interest income		105,673			-		279,743					543,390
Interest expense		-			-		-					(12,625	)
Total other income and expense		105,673			-		279,743			-		530,765

Loss from continuing operations		(954,862	)		-		(5,170,782	)		-		(8,125,505	)

Income from discontinued operations, net of income tax of $0, $5,000, $0, $10,000, and $0		-			36,860		-			66,455		-
Net Income (Loss)	$	(954,862	)	$	36,860	$	(5,170,782	)	$	66,455	$	(8,125,505	)

Income (loss) per common share - basic and diluted
From continuing operatons	$	(0.01	)	$	0.00	$